Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study by Morelli, A. et al.
CRITICAL CARE
Effects of short-term simultaneous infusion of dobutamine and
terlipressin in patients with septic shock: the DOBUPRESS study†
A. Morelli1*, C. Ertmer2, M. Lange2, M. Du¨nser3, S. Rehberg2, H. Van Aken2,
P. Pietropaoli1 and M. Westphal2
1Department of Anesthesiology and Intensive Care, University of Rome ‘La Sapienza’, Viale del Policlinico
155, 00161 Rome, Italy. 2Department of Anesthesiology and Intensive Care, University Hospital of Muenster,
Albert-Schweitzer-Str. 33, 48149 Muenster, Germany. 3Department of Intensive Care Medicine, University
of Bern, 3010 Bern, Switzerland
*Corresponding author. E-mail: andrea.morelli@uniroma1.it
Background. Terlipressin bolus infusion may reduce cardiac output and global oxygen supply.
The present study was designed to determine whether dobutamine may counterbalance the
terlipressin-induced depression in mixed-venous oxygen saturation (SvO2) in patients with cat-
echolamine-dependent septic shock.
Methods. Prospective, randomized, controlled study performed in a university hospital inten-
sive care unit. Septic shock patients requiring a continuous infusion of norepinephrine (0.9 mg
kg21 min21) to maintain mean arterial pressure (MAP) at 70 (SD 5) mm Hg were randomly
allocated to be treated either with (i) sole norepinephrine infusion (control, n¼20), (ii) a single
dose of terlipressin 1 mg (n¼19), or (iii) a single dose of terlipressin 1 mg followed by dobuta-
mine infusion titrated to reverse the anticipated reduction in SvO2 (n¼20). Systemic, pulmonary,
and regional haemodynamic variables were obtained at baseline and after 2 and 4 h.
Laboratory surrogate markers of organ (dys)function were tested at baseline and after 12
and 24 h.
Results. Terlipressin (with and without dobutamine) infusion preserved MAP at 70 (5) mm
Hg, while allowing to reduce norepinephrine requirements to 0.17 (0.2) and 0.2 (0.2) mg kg21
min21, respectively [vs1.4 (0.3) mg kg21 min21 in controls at 4 h; each P,0.001]. The terlipres-
sin-linked decrease in SvO2 was reversed by dobutamine at a mean dose of 20 (8) mg kg
21
min21 [SvO2 at 4 h: 59 (11)% vs 69 (12)%, P¼0.028].
Conclusions. In human catecholamine-dependent septic shock, terlipressin (with and
without concomitant dobutamine infusion) increases MAP and markedly reduces norepi-
nephrine requirements. Although no adverse events were noticed in the present study, poten-
tial benefits of increasing SvO2 after terlipressin bolus infusion need to be weighted against the
risk of cardiovascular complications resulting from high-dose dobutamine.
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Aggressive fluid challenge and administration of
catecholamines play a pivotal role in the current treatment
regimen of patients with septic shock. Owing to adrenergic
and post-receptor abnormalities in sepsis, however, the
efficacy of catecholamines often gradually decreases over
time,1 2 necessitating incremental doses to counteract
arterial hypotension. Excessive catecholamine concen-
trations, in turn, may contribute to major side-effects (e.g.
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tachyarrhythmias or pulmonary hypertension), thereby
further impairing cardio-circulatory functions.3
During the last years, arginine vasopressin and terlipres-
sin have been identified as useful adjunct vasopressors in
the treatment of catecholamine-dependent septic shock.4–11
Since terlipressin is a pro-drug with a long effective half-
life of approximately 6 h, it is usually given as intermittent
bolus injection.8 This approach, however, may contribute
to an overshooting increase in systemic vascular resistance
and a marked reduction in cardiac index (CI),12 13 thereby
compromising oxygen delivery index (DO2I) and mixed-
venous oxygen saturation (SvO2).
We hypothesized that dobutamine, a synthetic catechol-
amine with predominantly b1-adrenergic properties, may
reverse the terlipressin-associated depression in global
oxygen supply in patients with catecholamine-dependent
septic shock. Therefore, the primary endpoint of this pro-
spective, randomized, controlled, open-labelled, clinical
pilot study was to determine, whether dobutamine is a
useful inotropic agent to reverse the reduction in SvO2
resulting from terlipressin bolus infusion. Secondary end-
points included differences in norepinephrine require-
ments, systemic and regional haemodynamics, and organ
function between the groups.
Methods
Patients
The study was performed in an 18-bed multidisciplinary
intensive care unit. It was approved by the local insti-
tutional ethics committee, and informed consent was
obtained from the patients’ next of kin. We enrolled
patients who fulfilled the criteria of catecholamine-
dependent septic shock.14 Enrolment of the patients started
in November 2005 and ended in October 2006. All
patients eligible for the study were included when the nor-
epinephrine dose required to maintain mean arterial
pressure (MAP) between 70 (5) mm Hg reached 0.9 mg
kg21 min21, despite adequate volume resuscitation [pul-
monary artery occlusion pressure (PAOP)¼12–15 mm Hg
and central venous pressure (CVP)¼8–12 mm Hg].
Exclusion criteria were age ,18 yr, pronounced cardiac
dysfunction (i.e. CI2.2 litre min21 m22 in the presence
of PAOP.18 mm Hg, significant valvular heart disease,
present or suspected coronary artery disease), pregnancy,
present or suspected acute mesenteric ischaemia or vaso-
spastic diathesis (e.g. Raynaud’s syndrome or related
diseases).
From 180 screened septic patients, 70 consecutive
patients met the inclusion criteria. Among these, 10
patients were excluded before randomization because of
low CI (i.e. 2.2 litre min21 m22 in the presence of
PAOP.18 mm Hg). The remaining 60 patients were
enrolled in the present study.
All patients received mechanical ventilation using a
volume-controlled mode. The ventilatory settings remained
unchanged throughout the study. All patients were sedated
with sufentanil and midazolam.
Measurements
Systemic haemodynamic monitoring of the patients
included a pulmonary artery catheter (7.5 F, Edwards
Lifesciences, Irvine, CA, USA) and a radial artery cath-
eter. MAP, right atrial pressure (RAP), mean pulmonary
arterial pressure (MPAP), and PAOP were measured at
end-expiration. HR was analysed from a continuous
recording of ECG with ST segments monitored. CI was
measured using the continuous thermodilution technique
(Vigilance IIw, Edwards Lifesciences). Arterial and mixed
venous blood samples were taken to determine oxygen
tensions and saturations, carbon dioxide tensions, standard
bicarbonate, and base excess (BE). SvO2 was measured
discontinuously by intermittent mixed-venous blood gas
analyses. Systemic vascular resistance index (SVRI), pul-
monary vascular resistance index (PVRI), left-ventricular
stroke work index (LVSWI), right-ventricular stroke work
index (RVSWI), DO2I, oxygen consumption index (VO2I),
and oxygen extraction ratio (O2-ER) were calculated using
standard formulae.
Regional haemodynamic monitoring of the patients was
performed using a 4 F oximetry thermo-dye dilution cath-
eter (PV2024L, Pulsion Medical System AG, Munich,
Germany) inserted through the femoral artery for the
determinations of plasma disappearance rate of indocya-
nine green (PDR) and blood clearance of indocyanine
green related to body surface area (CBI). PDR and CBI
were determined with the Cold Z-021 system (Pulsion
Medical System AG) using an established protocol.15 16 In
addition, an air-tonometer (Tonocap, Datex-Ohmeda,
Helsinki, Finland) was inserted via the naso-gastric route
for gastric mucosal carbon dioxide tension measurement
and for the calculation of the gradient between gastric
mucosal and arterial PCO2 (Pg-aCO2).
Arterial blood samples were drawn and analysed for
pH, arterial lactate, aspartate aminotransferase (ASAT),
alanine aminotransferase (ALAT), total bilirubin (BILT),
international normalized ratio (INR), activated partial
thromboplastin time ratio (aPTTr), and cardiac troponin
I (cTnI). Urine samples were collected to assess urinary
output.
Study design
Sixty septic shock patients requiring norepinephrine doses
of 0.9 mg kg21 min21 to maintain MAP at 70 (5) mm Hg,
despite adequate volume resuscitation, were randomized
to one of the three study groups (n¼20 each) using a
computer-based procedure. In the ‘control group’ (Group 1),
norepinephrine infusion was titrated to maintain the
defined threshold MAP of 70 (5) mm Hg. Whereas patients
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allocated to the ‘terlipressin group’ (Group 2) received a
single bolus dose of terlipressin 1 mg, the ‘terlipressin-
dobutamine group’ (Group 3) was treated with a combi-
nation therapy consisting of a single bolus dose of terli-
pressin 1 mg and a titrated infusion of dobutamine. In the
latter group, dobutamine infusion was started immediately
after terlipressin administration at a rate of 3 mg kg21
min21 and was progressively increased (in steps of 1–3
mg kg21 min21) to reverse the anticipated,
terlipressin-associated depression in SvO2, and thus to
maintain SvO2 at baseline (Fig. 1). Dobutamine in doses up
to 20 mg kg21 min21 was allowed to increase SvO2.
Fluid challenge (hydroxyethyl starch 6% 130/0.4) was
performed to maintain PAOP and CVP at baseline +3
mm Hg during the 4 h study period. Packed red blood
cells were transfused when Hb concentrations decreased
below 8 g dl21. In all patients treated with terlipressin,
norepinephrine was titrated to maintain MAP at 70 (5) mm
Hg. All other medications were held constant.
Systemic, pulmonary, and regional haemodynamic
measurements, and blood gases, were determined at base-
line, and 2 and 4 h after randomization.
Surrogate variables of organ (dys)function and injury
(ASAT, ALAT, BILT, INR, aPTTr, and cTnI) were ana-
lysed at baseline, and 12 and 24 h after randomization.
Likewise, arterial lactate concentrations and urinary
output were determined at baseline, and 2 and 4 h after
randomization.
In patients surviving the 4 h intervention period, norepi-
nephrine was titrated to maintain MAP at 70 (5) mm Hg.
Dobutamine infusion was adjusted to keep SvO2 at baseline.
None of the patients received further terlipressin infusions.
Statistical analysis
Sigma Stat 3.10 software (SPSS, Chicago, IL, USA) was
used for statistical analysis. On the basis of a power analy-
sis (expected standard deviation of residuals¼15%, desired
power¼80%, and an alpha error¼5%), we determined that
a sample size of n¼20 per group would be sufficient to
detect a 15% decrease in SvO2 in the TP group. After
testing for normal distribution (Kolmogorov–Smirnov
test), differences within and between the groups were ana-
lysed using a two-way analysis of variance for repeated
measurements. After confirming significant group differ-
ences over time, appropriate post hoc comparisons
(Student–Newman–Keuls) were performed. The number
of patients requiring norepinephrine infusion in each study
group was compared using Fisher’s exact test. For all stat-
istical tests, a P-value of ,0.05 was regarded as statisti-
cally significant. Data are expressed as means (SD), if not
otherwise indicated.
Fig 1 Study design. MAP, mean arterial pressure; CI, cardiac index.
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Results
Each of the 60 patients enrolled into the present study
completed the entire study period. One patient randomized
to Group 2, however, had to be excluded from data analy-
sis due to inappropriate weaning from norepinephrine (i.e.
norepinephrine infusion rate had not been adequately
reduced, although MAP levels exceeded goal values).
Demographic data
Baseline characteristics and causes of septic shock of the
59 patients analysed in the present study are summarized
in Tables 1 and 2, respectively. There were no differences
in age, sex, body weight, Simplified Acute Physiology
Score II (SAPS II), or time of norepinephrine infusion
between the groups before randomization. All patients
received i.v. hydrocortisone (200 mg day21 continuously
administered via an infusion pump). Five patients in
Group 1, and four patients in Groups 2 and 3 received acti-
vated protein C during the study period. All patients
included in the study survived the 4 h (haemodynamic)
and 24 h (laboratory) study period. Overall mortality was
not significantly different between the three study groups.
Systemic haemodynamic variables
There were no differences in haemodynamic variables and
norepinephrine doses between the groups at baseline.
When compared with Groups 1 and 3, CI was significantly
lower in Group 2 at 2 h (P¼0.031 and P¼0.002, respect-
ively; Fig. 2). Whereas the highest MAP was noticed in
Group 3 (P0.001 between Group 1 and Group 2), the
highest SVRI was recorded in patients allocated to Group
2 (P0.001 between Group 1 and Group 3; Fig. 2). In
addition, LVSWI was higher in Group 3 than in the two
other study groups (P¼0.006 between Group 1 and
P¼0.013 vs Group 2; Fig. 2). In patients allocated to
Group 2, RVSWI significantly decreased (P,0.001 compared
with baseline at 2 h; Table 3). Despite a time-dependent
decrease in HR in Group 2, HR was similar between the
groups. Besides a significantly higher PVRI in Group 3
when compared with Group 2 (P¼0.047), MPAP, PAOP,
and RAP remained unchanged during the intervention
period (each P.0.05; Table 3).
Oxygen transport, gas exchange, and acid–base
balance
There were no differences in oxygen transport variables
and acid–base balance between the groups at BL (Fig. 3;
Table 4). Whereas single terlipressin infusion reduced
DO2I (P¼0.031 between Group 1 and P¼0.009 vs Group
3 at 2 h; Fig. 3) and increased O2-ER (P¼0.004 between
Group 1 and P¼0.003 vs Group 3 at 2 h; Fig. 3), VO2I
remained unchanged (Table 4). When compared with
Groups 1 and 3, SvO2 was significantly reduced in patients
treated with sole terlipressin infusion (P¼0.034 between
Group 1 and P¼0.039 vs Group 3 at 2 h after randomiz-
ation; Fig. 3). There were no differences in pH, PaCO2,
PaO2, SaO2, BE, and Hb concentrations between the groups
(each P.0.05; Table 4).
Regional haemodynamic variables and organ
function
All investigated surrogate markers of organ (dys)function
were similar between the groups at BL. During the inter-
vention period, there was no difference in mucosal and
regional blood flow variables (Pg-aCO2, PDR, and CBI). In
addition, surrogate parameters of hepatic function and
injury (BILT, ASAT, and ALAT), coagulation system
(INR and aPTTr), and myocardial injury (cTnI) were
similar between the groups (Table 5). However, terlipres-
sin (with and without additional dobutamine infusion)
increased urinary output when compared with baseline
values (P,0.001 in Group 2 and P¼0.028 in Group 3 at 4
h; Table 5). Arterial lactate significantly increased over
time in the control group (P¼0.008) and tended to
increase when compared with the terlipressin group
(P¼0.084 at 4 h after randomization; Fig. 3).
Table 1 Baseline and outcome characteristics of study patients. Data are
presented as mean (range), or mean (SD), if not indicated otherwise. SAPS II,
Simplified Acute Physiology Score II; NE, norepinephrine; ICU, intensive
care unit; Group 1, control group; Group 2, terlipressin group; Group 3,
terlipressin–dobutamine group
Group 1
(n520)
Group 2
(n519)
Group 3
(n520)
Age (yr) 67 (29–83) 66 (28–84) 66 (37–82)
Sex (male/female) 14/6 13/6 16/4
Body weight (kg) 75 (14) 77 (17) 77 (15)
SAPS II 59 (10) 60 (12) 61 (12)
NE infusion before
randomization (h)
40 (15) 40 (14) 39 (23)
ICU mortality (%) 70 63 70
ICU stay (days) 14 (10) 16 (10) 15 (10)
ICU stay of survivors
(days)
23 (11) 24 (6) 19 (9)
Table 2 Causes of septic shock of study patients. Data are presented as
number (n). Group 1, control group; Group 2, terlipressin group; Group 3,
terlipressin–dobutamine group
Diagnoses Group 1
(n520)
Group 2
(n519)
Group 3
(n520)
Peritonitis 9 9 11
Pneumonia 5 6 5
Pancreatitis 2 2 0
Meningitis 0 1 2
Pulmonary abscess 0 1 0
Necrotizing fascitis 0 0 2
Endocarditis 2 0 0
Mediastinitis 2 0 0
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Norepinephrine and dobutamine requirements
Whereas norepinephrine requirements increased over time
in the control group, norepinephrine doses significantly
decreased in Groups 2 and 3 (each P,0.001; Fig. 4). In
eight patients in Group 2 and nine patients in Group 3,
respectively, norepinephrine was discontinued after terli-
pressin administration (Table 6). Apart from temporary
changes in skin colour (i.e. pallor) related to cutaneous
vasoconstriction after terlipressin injection, we did not
notice any skin lesions in the study population.
Patients allocated to Group 3 required a mean dobuta-
mine dose of 20 (8) mg kg21 min21 to reverse the
terlipressin-linked depression in SvO2. However, no
obvious clinical adverse effects related to infusion of high
dobutamine doses were noticed.
Since we originally determined the maximum dose of
dobutamine as 20 mg kg21 min21, we additionally per-
formed a per-protocol analysis excluding patients who
received more than the predetermined maximum dose.
Within this per-protocol analysis, seven patients were
excluded from Group 3. The mean dobutamine dose of the
remaining 13 patients was 15 (5) mg kg21 min21 and the
terlipressin-linked decrease in SvO2 was significantly
reversed [SvO2 at 4 h: 59 (11)% vs 69 (11)%, Group 2 vs
Group 3; P¼0.046]. The major results of both analyses
were thus the same.
Discussion
The major findings of the present study are (i) that terli-
pressin with and without additional dobutamine infusion
markedly increased MAP and reduced norepinephrine
requirements and (ii) that high dobutamine doses were
needed to reverse the terlipressin-associated depression in
SvO2.
In accordance with previous clinical studies,8 – 11 terli-
pressin was effective in increasing MAP and allowed sig-
nificant weaning from norepinephrine. Since we
administered a relatively high bolus dose of terlipressin (1
mg), MAP exceeded goal values of 70 (5) mm Hg in
some patients, despite discontinuation of norepinephrine
infusion. In this regard, it is important to underline that in
eight patients in Group 2 and in nine patients in Group 3,
norepinephrine was completely discontinued after terli-
pressin administration (Table 6).
Compared with the control group, however, terlipressin
bolus infusion was linked to significant reductions in CI,
DO2I, and SvO2. The depression in CI is a typical character-
istic of terlipressin bolus infusion8–11 17 and may be
explained by baroreceptor activation and an increase in
left ventricular afterload.18 Alternatively, the terlipressin-
associated reductions in CI and DO2I may also be explained
by a reduction of global oxygen demand or myocardial dys-
function in response to an increased afterload.
Fig 2 Systemic haemodynamics of study patients. Data are presented as mean values (SD). BL, baseline; HR, heart rate; CI, cardiac index; SVRI,
systemic vascular resistance index; LVSWI, left-ventricular stroke work index; *P,0.05 Group 1 vs Group 2; †P,0.05 Group 1 vs Group 3; ‡P,0.05
Group 2 vs Group 3; §P,0.05 vs BL (in all groups). Baseline data were obtained at the fixed norepinephrine dose of 0.9 mg kg21 min21.
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Recently, Broking and colleagues19 reported that
dobutamine is a useful agent to reverse the terlipressin-
associated suppressions in CI and global oxygen transport
in ovine endotoxaemia. However, the efficacy and
safety of a combination therapy with terlipressin and
dobutamine have not yet been determined in human septic
shock.
Dobutamine is a synthetic catecholamine with b1- and
b2-adrenergic properties. As a result of its positive inotro-
pic and chronotropic effects, dobutamine increases HR
and CI. In the present study, the combination of terlipres-
sin and dobutamine maintained MAP at threshold values
and reduced norepinephrine requirements. Notably, dobu-
tamine increased CI, DO2I, and SvO2 without increasing
HR. Since maintenance of adequate CI and SvO2 appears to
be beneficial in septic shock,20 the addition of dobutamine
may be rational if terlipressin infusion alone leads to a
reduction in SvO2. However, it is still debated whether or
not an increase in CI and DO2I represents a therapeutically
useful goal.20 21
The strong vasoconstrictive response after terlipressin
bolus infusion necessitated high incremental dobutamine
doses to reverse the depression in global oxygen transport.
Importantly, although we envisaged 20 mg kg21 min21 of
dobutamine as the maximal dose, seven patients (35%)
required higher doses [28 (6) mg kg21 min21 at 4 h] to
maintain SvO2 at baseline. In this context, it is noteworthy
that high doses of dobutamine may result in adverse
effects, such as increased myocardial oxygen demand,
tachyarrhythmias, or, in the presence of hypovolaemia, a
decrease in MAP.
Nevertheless, it has to be taken into consideration that
whereas dobutamine at 5 mg kg21 min21 is usually effica-
cious in normal subjects or in patients with non-septic
heart failure,22 23 it may be of poor efficacy in patients
with severe septic shock because of impaired signal trans-
duction and down-regulation of b-adrenergic receptors.24 25
However, it is worth mentioning that despite the high
dobutamine doses infused in the present study, no adverse
events were noticed, even in those patients who required
dobutamine dosages exceeding 20 mg kg21 min21. In this
regard, it may be especially important that there was no
increase in HR in patients treated with high dobutamine
doses and that troponin I concentrations were comparable
between the groups (Table 7). Although dobutamine infu-
sion was adjusted to maintain SvO2 at baseline, SvO2 values
were higher at the end of the intervention period. This
may be explained by discontinuous measurements of this
variable and the short intervention period that made it dif-
ficult to exactly adjust the dobutamine dose to re-establish
baseline SvO2 values.
Previous studies using vasopressin receptor agonists in
patients with septic shock after adequate fluid resuscitation
showed less or no unwanted side-effects in the splanchnic
circulation.6 9 26 27 In harmony with these findings, terli-
pressin did not increase the Pg-aCO2 gap in the present
study. Whereas dobutamine prevented the terlipressin-
associated impairments in CI and DO2I, we did not notice
differences between the three study groups in terms of
Pg-aCO2 gap. The absence of detrimental splanchnic
haemodynamic effects is also confirmed by the lack of
differences between the groups in PDR and CBI. On the
contrary, the absence of significant increases in arterial
lactate concentrations (when compared with the control
group) suggests a positive effect on oxygen balance and
tissue oxygenation in both terlipressin-treated groups.
However, since lactate generation during septic shock may
be fostered by catecholamines,28 the difference between
the terlipressin-treated groups and the control group
may have also been related to decreased norepinephrine
requirements.
Our results are in accordance with the recent study of
Asfar and colleagues.27 The latter authors reported that
although terlipressin decreased both cardiac output and
portal venous blood flow, it increased hepatic arterial
blood flow, thereby leading to an unaffected splanchnic
oxygen delivery and Pg-aCO2 gradient. In harmony with the
results of the liver perfusion measurements (i.e. PDR and
CBI), we did not find differences in terms of liver
Table 3 Haemodynamics and catecholamine requirements of study patients.
Data are presented as mean values (SD). Group 1, control group; Group 2,
terlipressin group; Group 3, terlipressin–dobutamine group. BL, baseline;
MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure;
PAOP, pulmonary arterial occlusion pressure; RAP, right atrial pressure;
PVRI, pulmonary vascular resistance index; RVSWI, right-ventricular stroke
work index. *P,0.05 Group 2 vs Group 1; †P,0.05 vs BL (in all groups);
‡P,0.05 Group 3 vs Group 1; §P,0.05 Group 3 vs Group 2. Baseline data
were obtained at the fixed norepinephrine dose of 0.9 mg kg21 min21
Variable BL 2 h 4 h
MAP (mm Hg)
Group 1 (n¼20) 73 (4) 73 (3) 74 (3)
Group 2 (n¼19) 74 (2) 78 (7)*,† 78 (7)*,†
Group 3 (n¼20) 72 (3) 85 (16)†,‡,§ 80 (12)†,‡
MPAP (mm Hg)
Group 1 (n¼20) 26 (5) 26 (5) 26 (5)
Group 2 (n¼19) 26 (5) 25 (5) 27 (5)
Group 3 (n¼20) 27 (5) 28 (5) 28 (5)
PAOP (mm Hg)
Group 1 (n¼20) 14 (2) 14 (2) 14 (2)
Group 2 (n¼19) 14 (2) 15 (2) 15 (2)
Group 3 (n¼20) 15 (2) 16 (2) 16 (2)
RAP (mm Hg)
Group 1 (n¼20) 12 (4) 12 (3) 12 (3)
Group 2 (n¼19) 12 (2) 12 (2) 11 (3)
Group 3 (n¼20) 11 (3) 12 (3) 12 (3)
PVRI (dyne s cm25 m2)
Group 1 (n¼20) 255 (79) 251 (92) 261 (102)
Group 2 (n¼19) 259 (160) 302 (188)†,§ 322 (155)
Group 3 (n¼20) 261 (111) 239 (112) 223 (123)
RVSWI (g m22 beat21)
Group 1 (n¼20) 8 (3) 7 (3) 7 (3)
Group 2 (n¼19) 8 (4) 6 (3)† 8 (4)
Group 3 (n¼20) 9 (3) 10 (4) 10 (3)
Dobutamine requirements
(mg kg21 min21)
Group 1 (n¼20) 0 0 0
Group 2 (n¼19) 0 0 0
Group 3 (n¼20) 0 20 (8) 20 (8)
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enzymes and BILT 24 h after terlipressin administration,
suggesting a lack of drug-related acute hypoxic liver
injury.
In line with previous clinical trials,9 – 11 urinary output
increased over time in both terlipressin-treated groups,
despite its potential antidiuretic effect. In this context, it is
noteworthy that vasopressin analogues may increase glo-
merular filtration rate by increasing resistance of efferent
glomerular arterioles without constricting afferent arter-
ioles.29 In addition, terlipressin is less likely to produce
antidiuretic effects when compared with arginine vasopres-
sin due to the higher V1 receptor selectivity of terlipressin.
In the light of our results, we would like to emphasize
that potential benefits of increasing SvO2 after terlipressin
infusion need to be weighted against the potential risk of
cardiovascular complications resulting from high dose
dobutamine infusion. Future large-scale studies are needed
to clarify whether the combination of terlipressin and
dobutamine is superior to standard therapy with norepi-
nephrine. It also remains to be determined whether the
reductions in CI and SvO2 after terlipressin infusion have to
be regarded as detrimental effects, or as a surrogate of
reduced metabolic demands.
The present study has some limitations that need to be
acknowledged. First, direct measurements of regional and
local splanchnic blood flow in septic shock patients would
be invasive, require special skills and instruments that are
not readily available at the bedside. Thus, in the present
study, hepatosplanchnic perfusion was assessed using PDR
and CBI; mucosal blood flow was evaluated by gastric
tonometry. Secondly, terlipressin was administered at a
fixed dose without adaptation for body weight. However,
body weight of the enrolled patients was similarly distribu-
ted within the three study groups. In addition, terlipressin
was administered as a relatively high dose bolus infusion,
which resulted in decreases in CI, DO2I, and SvO2. A con-
tinuous, low-dose infusion of terlipressin may prevent
these unwanted side-effects30 31 and thus may reduce
dobutamine requirements. Thirdly, since the effects of the
combination therapy of terlipressin and dobutamine were
not exactly predictable, for safety reasons the present trial
was designed as a short-term haemodynamic pilot study.
Therefore, we investigated only a small number of septic
shock patients treated with a single dose of terlipressin to
evaluate the effects of a titrated dobutamine infusion on
cardiopulmonary haemodynamics and global oxygen trans-
port over a brief period. Hence, we cannot rule out the
possibility of adverse metabolic alterations or side-effects
in response to repeated administration of terlipressin alone
or in combination with dobutamine for a prolonged
Fig 3 Systemic oxygen delivery, oxygen extraction, and mixed-venous oxygen saturation of study patients. Data are presented as mean values (SD).
BL, baseline; DO2I, systemic oxygen delivery index; O2-ER, oxygen extraction rate; SvO2, mixed-venous oxygen saturation; *P,0.05 Group 1 vs Group
2; †P,0.05 Group 1 vs Group 3; ‡P,0.05 Group 2 vs Group 3; §P,0.05 vs BL (in all groups). Baseline data were obtained at the fixed norepinephrine
dose of 0.9 mg kg21 min21.
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period. Fourthly, although Luckner and colleagues3
reported a positive correlation between high norepi-
nephrine doses and mortality, it is still unclear whether the
reduction of norepinephrine dosages per se represents a
therapeutic target.
In conclusion, this is the first prospective, randomized
clinical study showing that terlipressin bolus adminis-
tration (with and without concomitant dobutamine infu-
sion) significantly reduces norepinephrine requirements in
septic shock patients and that high doses of dobutamine
are needed to reverse the terlipressin-linked depression in
SvO2. In this context, it is noteworthy that dobutamine infu-
sion in the present study was not associated with any clini-
cally obvious cardiovascular side-effects. However,
large-scale studies are needed to clarify whether combined
terlipressin and dobutamine infusion improves the overall
outcome when compared with norepinephrine infusion.
In addition, future trials are warranted to investigate
whether continuous low-dose terlipressin infusion, or inter-
mittent infusion of low-dose terlipressin boli, may omit
decreases in CI and SvO2,
30 and thereby reduce inotropic
requirements.
Table 5 Regional haemodynamic variables of study patients. Data are
presented as mean values (SD). TP, Group 2, terlipressin; Group 3, terlipressin
and dobutamine; BL, baseline; Pg-aCO2, difference between gastric mucosal
and arterial carbon dioxide partial pressure; CBI, blood clearance of
indocyanine green; PDR, plasma disappearance rate of indocyanine green.
†P,0.05 vs BL (in all groups). Baseline data were obtained at the fixed
norepinephrine dose of 0.9 mg kg21 min21
Variable BL 2 h 4 h
Pg-aCO2 (mm Hg)
Group 1 (n¼20) 14 (7) 17 (9) 15 (7)
Group 2 (n¼19) 14 (5) 17 (5) 14 (4)
Group 3 (n¼20) 14 (7) 17 (8) 14 (8)
CBI (ml min21 m22)
Group 1 (n¼20) 416 (192) 418 (192) 401 (155)
Group 2 (n¼19) 428 (182) 399 (150) 401 (141)
Group 3 (n¼20) 365 (167) 429 (181) 465 (209)
PDR (%)
Group 1 (n¼20) 15 (5) 15 (5) 15 (5)
Group 2 (n¼19) 16 (6) 16 (6) 15 (5)
Group 3 (n¼20) 15 (6) 17 (7) 17 (7)
Urinary output (ml
h21)
Group 1 (n¼20) 103 (45) 103 (72) 96 (48)
Group 2 (n¼19) 100 (64) 160 (128)† 147 (119)†
Group 3 (n¼20) 103 (56) 134 (69)† 130 (76)†
Table 4 Gas exchanges, oxygen consumption, acid–base variables, and
haemoglobin concentrations of study patients. Data are presented as mean
values (SD). TP, Group 2, terlipressin; Group 3, terlipressin and dobutamine;
BL, baseline; PaO2, arterial oxygen partial pressure; SaO2, arterial oxygen
saturation; PaCO2, arterial carbon dioxide partial pressure; BE, arterial base
excess. VO2I, systemic oxygen consumption index; Baseline data were
obtained at the fixed norepinephrine dose of 0.9 mg kg21 min21
Variable BL 2 h 4 h
pH [2log10 c(H
þ)]
Group 1 (n¼20) 7.35 (0.07) 7.35 (0.09) 7.35 (0.1)
Group 2 (n¼19) 7.37 (0.06) 7.38 (0.07) 7.39 (0.06)
Group 3 (n¼20) 7.36 (0.1) 7.36 (0.08) 7.35 (0.09)
PaO2 (mm Hg)
Group 1 (n¼20) 131 (48) 129 (44) 131 (43)
Group 2 (n¼19) 147 (59) 140 (57) 128 (51)
Group 3 (n¼20) 134 (49) 109 (42) 135 (48)
SaO2 (%)
Group 1 (n¼20) 98 (2) 97 (5) 97 (5)
Group 2 (n¼19) 98 (4) 98 (4) 97 (5)
Group 3 (n¼20) 97 (3) 95 (6) 97 (5)
PaCO2 (mm Hg)
Group 1 (n¼20) 43 (6) 44 (8) 44 (9)
Group 2 (n¼19) 42 (5) 43 (7) 43 (6)
Group 3 (n¼20) 46 (9) 46 (9) 47 (10)
BE (mmol litre21)
Group 1 (n¼20) 21.7 (5) 21.8 (6) 21.7 (6)
Group 2 (n¼19) 0.2 (4) 20.1 (4) 0.1 (4)
Group 3 (n¼20) 0.4 (6) 20.2 (5) 20.5 (5)
VO2I (ml min
21 m22)
Group 1 (n¼20) 166 (38) 163 (43) 163 (41)
Group 2 (n¼19) 163 (42) 158 (31) 155 (30)
Group 3 (n¼20) 155 (43) 163 (45) 160 (43)
Haemoglobin (g
litre21)
Group 1 (n¼20) 89 (10) 89 (10) 88 (12)
Group 2 (n¼19) 91 (16) 89 (15) 89 (15)
Group 3 (n¼20) 91 (10) 87 (10) 86 (10)
Table 6 Norepinephrine requirements of study patients. Data show the
absolute number and percentage of patients requiring norepinephrine infusion
in each group at each time point. BL, baseline; *P,0.005 Group 1 vs Group
2; †P,0.005 Group 1 vs Group 3
Time point Group 1
(n520)
Group 2
(n519)
Group 3
(n520)
BL 20 (100%) 19 (100%) 20 (100%)
2 h 20 (100%) 11 (58%)* 11 (55%)†
4 h 20 (100%) 12 (63%)* 10 (50%)†
Fig 4 Norepinephrine requirements. Data are presented as mean values
(SD). BL, baseline; NE, norepinephrine; *P,0.05 Group 1 vs Group 2;
†P,0.05 Group 1 vs Group 3. Baseline data were obtained at the fixed
norepinephrine dose of 0.9 mg kg21 min21.
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